ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
Signatera Lymphoma Patient Discussion Guide
Read More
-
Signatera Cancer Care Patient Discussion Guide
Read More
-
Signatera Gynecologic Patient Discussion Guide
Read More
-
Signatera Lung Patient Discussion Guide
Read More
-
Signatera CRC Patient Discussion Guide
Read More
-
Signatera Bladder Patient Discussion Guide
Read More
-
Signatera Breast Patient Discussion Guide
Read More
-
Navigating Low-Level ctDNA Positive: Interpretation, Context and Actionability
Watch Video
-
Navigating MIBC management: Integrating ctDNA into clinical practice
Watch Video
-
A clinical perspective from Dr. Siddharth Sheth
See how Signatera™ MRD testing flagged HNSCC recurrence before CT imaging, providing a lead-time advantage that can inform treatment.
Watch Video
-
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
Kataoka, K, et al. JAMA Oncology, 2026
Read More
-
Redefining HNSCC Management with Signatera™ MRD Testing: A Multidisciplinary Perspective
Watch Video
-
My patient is Signatera-positive. Now What?
Watch Video
-
Molecular Residual Disease (MRD) Testing: Advancing Clinical Decision-Making in Breast Cancer
Read More
-
MRD Insights for Radiation Oncology in NSCLC
Watch Video
-
Anal One Pager
Read More
-
HCC One Pager
Read More
-
MDT+TOMR One Pager
Read More
-
Gastroesophageal One Pager
Read More
-
Loading More...
